Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Early Stage RNAi Therapeutics Pipeline Transcript

Jul 17, 2020 / 01:30PM GMT
Release Date Price: $158.36 (+1.49%)
Joshua Brodsky
Alnylam Pharmaceuticals, Inc. - Director of IR & Corporate Communications

Good morning, everyone, and thank you for joining us today for this RNAi Roundtable, where we will be discussing some of our early-stage investigational RNAi therapeutics programs. I'm Josh Brodsky, Director of Investor Relations and Corporate Communications at Alnylam. I'm joined today by Vasant Jadhav, Vice President of Research; Josh Friedman, Senior Director of Clinical Research; and Tanya Fischer, Vice President of Clinical Development. In just a moment, I'll hand it over to Vasant, but let me start quickly with a few brief comments.

Today's RNAi roundtable is part of a series of roundtable webinars that we'll be hosting this summer and early fall to review progress across our various programs. Today's event is expected to run approximately 60 minutes. Vasant will moderate a Q&A session at the conclusion of the presentations. If you'd like to submit a question, you can do so at any time during the event by typing your question in the 'Ask a Question' field. Finally, as a reminder, we will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot